Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR5 | Q9H1C0 | 7/20 | 1.00 |
| ▸ | LPAR1 | Q92633 | 14/20 | 0.69 |
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.69 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.61 |
| ▸ | LPAR4 | Q99677 | 6/20 | 0.61 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.61 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258136 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL7820593 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL28064781 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL26603866 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL12621099 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL7829804 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258161 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258032 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL258094 | 1.00 | LPAR5 (1.00) | LPAR5LPAR1LPAR3LPAR2LPAR4 | |
| SCHEMBL250888 | 0.98 | LPAR5 (0.97) | LPAR5LPAR1LPAR3LPAR2LPAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001012838-A2 | COMPOUNDS WHICH MODULATE THE ACTIVITY OF AN LPA RECEPTOR | ATAIRGIN TECHNOLOGIES, INC. (US) | 2001-02-22 | — | — | WO | claimed |
| US-20130244984-A1 | Ceramide Production Promoter | KAO CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130244984-A1 | Ceramide Production Promoter | KAO CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-8440645-B2 | Ceramide production promoter | KAO CORPORATION (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8440645-B2 | Ceramide production promoter | KAO CORPORATION (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8440645-B2 | Ceramide production promoter | KAO CORPORATION (JP) | 2013-05-14 | — | — | US | disclosed |
| CN-102438629-A | Ceramide production promoter | KAO CORP | 2012-05-02 | — | — | CN | disclosed |
| US-7968607-B2 | Cosmetics 1-isostearylglycerol-3-Sulfate Sodium Salt, used for constriction of keratinocytes; aging resistance | KOA CORPORATION (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20110105439-A1 | Ceramide Production Promoter | KAO CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105439-A1 | Ceramide Production Promoter | KAO CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
| US-6949528-B1 | Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof | GODDARD JOHN G | 2005-09-27 | — | — | US | disclosed |
| US-6949529-B2 | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | SKY HIGH, LLC (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1024812-A4 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | SKY HIGH LLC (US) | 2004-05-19 | — | — | EP | disclosed |
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | KAO CORPORATION (JP) | 2004-01-15 | — | — | US | disclosed |
| US-20030149002-A1 | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | SKY HIGH, LLC. | 2003-08-07 | — | — | US | disclosed |
| EP-1325737-A1 | SKIN PORE MINIMIZERS AND SKIN ELASTICITY IMPROVERS | Kao Corporation (JP) | 2003-07-09 | — | — | EP | disclosed |
| US-6495532-B1 | PRESERVATION AND TREATMENT OF ORGANS FOR TRANSPLANTATION WITH SUCH AS 3-OLEOYL-2-METHYL-1-THIOPHOSPHATE-GLYCERIDE AND A POTENTIATING COPONENT SUCH AS POLYETHYLENE GLYCOL, A PROTEIN OR A LIPID MEMBRANE | SKY HIGH, LLC | 2002-12-17 | — | — | US | disclosed |
| WO-2001012838-A2 | COMPOUNDS WHICH MODULATE THE ACTIVITY OF AN LPA RECEPTOR | ATAIRGIN TECHNOLOGIES, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| EP-1024812-A1 | COMPOSITIONS CONTAINING LYSOPHOSPHATIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | LXR BIOTECHNOLOGY INC. (US) | 2000-08-09 | — | — | EP | disclosed |
| WO-1998041213-A1 | COMPOSITIONS CONTAINING LYSOPHOSPHOTIDIC ACIDS WHICH INHIBIT APOPTOSIS AND USES THEREOF | LXR BIOTECHNOLOGY INC. (US) | 1998-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105439-A1 | Ceramide Production Promoter | CERS2, SPTLC1, SGMS1 | LPAR5 1170/4885LPAR1 491/4885LPAR3 707/4885 |
| US-20130244984-A1 | Ceramide Production Promoter | CERS2, SPTLC1, SGMS1 | LPAR5 1170/4885LPAR1 491/4885LPAR3 707/4885 |
| US-20040009140-A1 | Skin pore minimizers and skin elasticity improvers | CUTA, DSG1, OGA | LPAR5 115/4885LPAR1 26/4885LPAR3 77/4885 |
| US-20030149002-A1 | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof | LPAR5, LPAR2, LPAR6 | LPAR5 1/4885LPAR1 4/4885LPAR3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.